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Peak bone mass achieved in adolescence is a determinant of bone mass in later life. In order to identify genetic
variants affecting bone mineral density (BMD), we performed a genome-wide association study of BMD and
relatedtraitsin1518childrenfromtheAvonLongitudinalStudyofParentsandChildren(ALSPAC).Wecompared
results with a scan of 134 adults with high or low hip BMD. We identiﬁed associations with BMD in an area of
chromosome 12 containing the Osterix (SP7) locus, a transcription factor responsible for regulating osteoblast
differentiation (ALSPAC: P=5.8 3 10
24; Australia: P=3.7 3 10
24). This region has previously shown evidence
of association with adult hip and lumbar spine BMD in an Icelandic population, as well as nominal association
in a UK population. A meta-analysis of these existing studies revealed strong association between SNPs in the
Osterix region and adult lumbar spine BMD (P=9.9 3 10
211). In light of these ﬁndings, we genotyped a further
3692 individuals from ALSPAC who had whole body BMD and conﬁrmed the association in children as well (P
=5. 43 10
25). Moreover, all SNPs were related to height in ALSPAC children, but not weight or body mass
index, and when height was included as a covariate in the regression equation, the association with total body
BMD was attenuated. We conclude that genetic variants in the region of Osterix are associated with BMD in chil-
dren and adults probably through primary effects on growth.
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Bone accrual during childhood and adolescence is a
determinant of peak bone size and mass traits that are import-
ant determinants of bone structural strength in later life (1).
Although several environmental factors are thought to contrib-
ute to the population variance in peak bone mass and bone
size, genetic factors account for the majority of the variance
in these traits as reported in twin and family studies (2).
Indeed, familial resemblance of bone mineral density (BMD)
is greater in adolescence and early adulthood than in later
life (3,4). Furthermore, these familial inﬂuences upon BMD
are expressed as early as pre-puberty (5).
Contrary to the case in older individuals in whom bone mass
is also affected by age-related bone loss, bone mass in child-
hood largely reﬂects those processes involved in bone mass
acquisition, and as such shows distinct patterns of genetic
associations. For example, many of the genetic studies pub-
lished in relation to childhood BMD have reported associ-
ations with markers in osteoblast-related genes, such as
collagen type 1a2, osteocalcin, PTHR1, LRP5 and ESR1
(6–8).
Our understanding of the genetic inﬂuences on adult BMD
was recently advanced by two genome-wide association
studies (GWAS) in which BMD was analysed in relation to
.300 000 markers identiﬁed from the human HapMap
project (9,10), and a series of very large candidate gene
studies from the GENOMOS consortium (11–14). The two
genome-wide studies reported several associations with
SNPs in genes related to the OPG/RANKL system, which is
predominantly involved in regulating bone resorption. Inter-
estingly, the genome-wide studies and one of the candidate
gene studies found evidence of association with SNPs in
LRP5 (9,11) and ESR1 (10), suggesting shared genetic inﬂu-
ences on BMD in children and adults. In order to identify
additional genetic determinants of BMD, we applied the
genome-wide association approach to 1518 children from a
large population-based cohort in which BMD was assessed
by total DXA scans performed at 9.9 years of age (the
‘ALSPAC discovery set’) (15) as well as an Australian
sample of adult individuals with extremes of higher or lower
bone mineral densities (the ‘Australian Extremes’ set). We
subsequently identiﬁed a region near a promising candidate
gene that displayed suggestive evidence of association in
both scans. A meta-analysis of two existing genome-wide
studies (9,10) revealed strong combined evidence of associ-
ation at this locus in adults. We subsequently replicated the
association in a further 3692 children from the Avon Longi-
tudinal Study of Parents and Children (ALSPAC) cohort
who had whole body measures of BMD and DNA available
(the ‘ALSPAC replication set’).
RESULTS
Table 1 displays means and standard deviations of BMD, bone
mineral content (BMC), bone area, area-adjusted BMC
(aBMC) and other related measures for each of the three data-
sets used in this study. Values were comparable between the
ALSPAC discovery and replication sets, although individuals
in the replication set were slightly older, heavier and had
higher BMC and bone area values. The correlation between
the different bone phenotypes was high (i.e. rBMC-AREA=0.98,
rBMD-BMC=0.89, rBMD-Area=0.77 in the ALSPAC cohort) indi-
cating that we might expect SNPs to exhibit association with
more than one bone-related phenotype. Adult individuals in
the Australian cohort were taller and heavier than the
ALSPAC children. While it does not make sense to compare
the Australian and ALSPAC cohorts in terms of their bone
phenotypes (since one involves whole body DXA and the
other measurement at the femoral neck), we note that the dis-
tribution of BMD and BMC in the Australian sample was
bimodal reﬂecting the selection procedure applied to this
cohort.
Tables S1–S4 in the Supplementary Material display a full
list of SNPs that exhibit nominal evidence of association (P ,
10
24) with the bone phenotypes in the ALSPAC genome-wide
association scan. While no SNP passed a stringent threshold
required for genome-wide signiﬁcance in the ALSPAC discov-
ery set (0.05/315807=1.6   10
27), a number of SNPs in can-
didate genes displayed nominal associations with BMD,
BMC, bone area and/or aBMC obtained from whole body
DXA scans. These included the SNPs rs525735 (BMD: T =
3.16, P= 0.002; aBMC: T =4.30, P =1.9   10
25) and
rs168568 (BMD: T =3.48, P= 0.0005; BMC: T = 2.58, P =
0.01; aBMC: T =3.07, P= 0.002) in the gene OSMR, the
SNP rs1798802 (BMD: T = 23.18, P = 0.002; aBMC: T
= 23.70, P = 0.0002) in the gene CTNNB1, and several
SNPs residing in a linkage disequilibrium block near the
gene Osterix (Fig. 1 and Table 2). In contrast, SNPs in or
near RANKL (rs9594759, rs9594738), OPG (rs6993813,
rs6469804), ZBTB40 (rs7524102, rs6696981), the MHC
(rs3130340) and SNPs in or close to ESR1 (rs2504063,
rs851982, rs9479055, rs4870044, rs1038304, rs6929137,
rs1999805), which had previously displayed association with
hip and spine BMD in a recent Icelandic genome-wide associ-
ation study, did not show strong evidence of association in our
study (P . 0.01 across all phenotypes). Similarly, we did not
ﬁnd any evidence of association for the SNP rs4355801 (near
TNFRSF11B) which was recently identiﬁed in a European
study of hip and spine BMD involving 8557 participants (9),
although we did ﬁnd some evidence of association between
rs3736228 (in LRP5) and BMD in the same direction as
reported by Richards et al. (9) (P = 0.017).
Given the small size of our genome-wide scan, and conse-
quently the low power to detect quantitative trait loci, it is
likely that many of the top ‘hits’ listed in Supplementary
Material, Tables S1–S4 reﬂect type I error. Therefore, in
order to identify genuine variants that exhibit nominal
levels of association but do not meet the stringent levels
required for genome-wide signiﬁcance, we compared our
complete set of genome-wide results to an Australian
genome-wide association scan, which examined a sample of
adult individuals with high (66 individuals) or low (68 indi-
viduals) hip BMD, and identiﬁed regions of nominal associ-
ation in the same direction in both scans (i.e. P , 0.01).
Several SNPs showed evidence of association in both the
ALSPAC discovery set and the Australian extremes study
(see Supplementary Material, Table S5), including SNPs in
a large area of linkage disequilibrium (500 kb) on chromo-
some 12 which contained the strongest statistical evidence of
Human Molecular Genetics, 2009, Vol. 18, No. 8 1511Table 1. Mean and standard deviations of Study Population Characteristics in the ALSPAC GWAS discovery sample, the ALSPAC replication set and the
Australian Extremes Sample
ALSPAC discovery set (total= 1518
a:
females=778; males=740)
ALSPAC replication set (total= 4178
a:
females= 2062; males=2116)
Australian extremes (total=134
a:
females= 134; males= 0)
n Mean SD n Mean SD n Mean SD
Age (years) 1518 9.85 0.26 4178 9.94 0.34 134 67.01 7.67
Height (cm) 1507 139.61 6.18 4178 139.58 6.33 109 158.61 6.55
Weight (kg) 1516 34.20 6.77 4176 34.87 7.58 109 64.31 14.97
BMI (kg/m
2)
b 1506 17.44 2.58 4176 17.77 2.94 108 25.39 5.65
BMD (g/cm
2)
b 1418 0.78 0.05 3875 0.78 0.05 – – –
BMC (g)
b 1418 884.87 172.02 3875 897.60 184.87 – – –
Area (cm
2)
b 1418 1132.95 156.99 3875 1143.04 165.01 118 4.89 0.50
aTotal number of individuals genotyped in each dataset. Phenotypic data were not available for all individuals genotyped. In these situations, n displays
the total number of individuals that have phenotypic information available for the relevant trait.
bBonemeasurements refer towholebody lesshead valuesin the case of theALSPACdatasets,andthe femoralneck for the Australianextremescohort.Individuals
in the Australian cohort were speciﬁcally selected to have low or high BMD and thus average BMD and BMC values are not reported for this dataset.
Figure 1. A graphical representation of the region on chromosome 12 that displays nominal association in both the ALSPAC and Australian genome-wide
association scans. Gene tracks, location of SNPs (blue lines), linkage disequilibrium between markers and –log10 P-values for ALSPAC (upper) and Australian
(bottom) genome scans are shown. The strongest signals occur in and around the genes Osterix and AAAS, although linkage disequilibrium is strong and extends
across a wider region that includes the genes ESPL1, PFDN5 and MYG1.
1512 Human Molecular Genetics, 2009, Vol. 18, No. 8association in both scans (P , .001 in both scans, Sup-
plementary Material, Table S5, Fig. 1 and Table 2). While
the SNP rs4759021 which displayed the strongest evidence
of association with BMD in both scans (ALSPAC: standar-
dized beta = .134, SE =0.039, P= 0.0006; Australian scan:
OR= 2.75, P =0.001) lies in the gene AAAS, the extensive
linkage disequilibrium across this region means that a puta-
tive functional variant might lie within any one of a
number of different genes. Notably, the region included the
likely candidate gene Osterix (SP7), which encodes a tran-
scription factor responsible for regulating osteoblast differen-
tiation (16). The same SNPs were also reported to have
moderate associations in an Icelandic GWAS of hip (P =
3.5   10
22 to 3.3   10
23) and lumbar spine (P= 1.1  
10
24 to 1.0   10
26) BMD (10), as well as nominal associ-
ation in a European GWAS of femoral neck (P= 8.5  
10
23 to 5.0   10
22) and lumbar spine (P= 3.0   10
22 to
2.2   10
21) BMD (9), but did not achieve genome-wide sig-
niﬁcance in either study. Two of these SNPs (rs10876432 and
rs2016266) were subsequently followed up in the Icelandic
study, and showed further evidence of association to spine
BMD in an independent Icelandic sample (P =4.0   10
27
and P = 2.6   10
25, respectively), but not in a Danish and
Australian replication cohort (P . 0.05).
In order to quantify the amount of pre-existing evidence for
an association between these SNPs and BMD, we combined
results from the previously published Icelandic (10) and
Richards et al. (9) studies using Fisher’s inverse chi-square
test (Table 3). Using this method, we calculated an overall sig-
niﬁcance value for lumbar spine BMD of P =9.9   10
211 at
rs10876432, and an overall P = 2.8   10
210 at rs2016266.
For BMD measured at the femoral neck, the P-values were
3.1   10
25 in the case of rs10876432 and 7.9   10
24 at
rs2016266. There is thus strong evidence for an association
between these SNPs and adult lumbar BMD, and suggestive
evidence of association between these SNPs and adult
femoral neck BMD. Given the strong pre-existing evidence
for association at these SNPs, the presence of moderate associ-
ation signals in the ALSPAC and Australian genome-wide
scans, together with SP7’s obvious candidate gene status, we
were interested in whether these signals might replicate in
the remainder of the ALSPAC children. We chose not to
follow up the other SNPs listed in Supplementary Material,
Table S5 because of weaker evidence of association and
(lack of) candidacy.
Table 2 presents the results of the ALSPAC genome-wide
association study, the replication analysis in the full
ALSPAC cohort and the two analyses combined for the four
SNPs that exhibited the strongest evidence of association in
the discovery sets. In each case, the association is with
BMD, BMC and bone area, but not with aBMC. In addition,
when subject’s height is included as a covariate in the
regression equation, the association with BMD, BMC and
bone area attenuates (Table 4). Since bone size is determined
by skeletal growth, which in turn reﬂects a contribution of
longitudinal and periosteal bone growth, we examined associ-
ation of the SNPs with other growth-related phenotypes
including height, sitting height, leg length, weight and BMI.
Table 2. Association results for four SNPs in the region of Osterix in the initial ALSPAC genome-wide association scan, the ALSPAC replication dataset and the
two ALSPAC datasets combined
Phenotype SNP Minor
Allele
MAF
a Initial GWAS
b Replication set
b Combined set
b
n BETA
c SE
c P-value n BETA
c SE
c P-value n BETA
c SE
c P-value
BMD (g/cm
2)
rs2016266 G 0.33 1418 0.133 0.040 0.00082 3689 0.067 0.025 0.0063 5275 0.085 0.020 0.000031
rs4759021 A 0.32 1416 0.134 0.039 0.00058 3692 0.054 0.025 0.031 5272 0.075 0.020 0.00026
rs6580942 C 0.33 1416 0.118 0.039 0.0025 3691 0.071 0.025 0.0045 5273 0.082 0.020 0.000054
rs10876432 G 0.29 1418 0.131 0.041 0.0013 3610 0.062 0.025 0.0142 5160 0.081 0.021 0.00012
BMC (g)
rs2016266 G 0.33 1418 0.130 0.040 0.0012 3689 0.066 0.025 0.0087 5275 0.082 0.020 0.000061
rs4759021 A 0.32 1416 0.124 0.039 0.0017 3692 0.045 0.025 0.077 5272 0.066 0.020 0.0013
rs6580942 C 0.33 1416 0.108 0.039 0.0063 3691 0.062 0.025 0.013 5273 0.072 0.020 0.00041
rs10876432 G 0.29 1418 0.124 0.041 0.0027 3610 0.070 0.026 0.0068 5160 0.087 0.021 0.000043
Bone area
(cm
2)
rs2016266 G 0.33 1418 0.126 0.041 0.0019 3689 0.065 0.025 0.0091 5275 0.081 0.020 0.000078
rs4759021 A 0.32 1416 0.116 0.040 0.0038 3692 0.040 0.025 0.116 5272 0.061 0.021 0.0029
rs6580942 C 0.33 1416 0.100 0.040 0.0125 3691 0.055 0.025 0.028 5273 0.065 0.021 0.0014
rs10876432 G 0.29 1418 0.119 0.042 0.0044 3610 0.071 0.026 0.0057 5160 0.088 0.021 0.00003
aBMC (g)
rs2016266 G 0.33 1418 0.022 0.040 0.5844 3689 0.008 0.025 0.749 5275 0.012 0.021 0.570
rs4759021 A 0.32 1416 0.041 0.040 0.300 3692 0.026 0.025 0.287 5272 0.027 0.021 0.187
rs6580942 C 0.33 1416 0.040 0.040 0.308 3691 0.037 0.025 0.136 5273 0.038 0.020 0.063
rs10876432 G 0.29 1418 0.028 0.042 0.499 3610 0.000 0.026 0.994 5160 0.004 0.021 0.853
aMinor allele frequency in combined sample.
bDiscrepancy in sample size between the combined dataset and the sum of the initial and replication datasets is a result of missing genotype data in the
genome-wide scan. The combined dataset represents single SNP genotyping carried out across the entire ALSPAC cohort at selected SNPs—i.e. not a mixture of
genome-wide association data and single SNP genotypes.
cStandardized beta coefﬁcients and standard errors. The sign of the beta coefﬁcient indicates the direction of effect per addition of minor allele.
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associated with measures of height, but not with weight or
BMI (although the SNP rs10876432 showed some evidence
of an effect on weight in the same direction). Finally, in
order to determine whether the association between the
SNPs and the different bone measures was robust, we only
included pre-pubertal children in the analyses (80% of chil-
dren). Although there was some increase in P-values (which is
to be expected given the smaller sample size), the estimated
standardized regression coefﬁcients were roughly similar to
the total analysis (data not shown).
DISCUSSION
To our knowledge, this report describes the ﬁrst genome-wide
association study of BMD in a population of children. Using
this approach, we were able to identify several common var-
iants in an area of linkage disequilibrium on chromosome
12q13 that were associated with total body BMD as measured
at 9.9 years. Given the high correlation between markers
across this region, we cannot unequivocally localize the
association signal to any one gene. For example, one of the
SNPs rs4759021 lies in the AAAS gene, which has been
implicated in ‘Triple A Syndrome’, in which osteopenia
occasionally occurs (17,18). We also note that our association
signal is very strong around the candidate gene Osterix. Based
upon studies of osterix null mice, Osterix is thought to act as
an osteoblast-speciﬁc transcription factor down-stream to
Runx-2, serving as a ‘master gene’ in determining osteoblast
differentiation (19). In spite of the strong rationale for a role
of genetic variants in Osterix inﬂuencing bone mass acqui-
sition, we are not aware of any previous genetic studies in
humans highlighting this association.
Although our discovery set was underpowered for genome-
wide association analysis, we observed a similar association in
our replication cohort. Our ﬁndings are also consistent with a
large genome-wide association study of Icelandic individuals
that documented strong evidence of association between
markers in the same region and adult hip and lumbar spine
BMD (10), and by an association between the SNPs and hip
BMD in a small Australian sample of adults with extremely
high and low BMD. In fact, while this manuscript was under
review, a follow-up study from the same Icelandic group
found signiﬁcant evidence of association between the marker
rs10876432 near the Osterix gene with lumbar spine
BMD (20).
Whereas the variants identiﬁed in this study were related to
total body BMC, BMD and bone area, which are all size-
dependent, no association was observed with aBMC (a
measure which has been adjusted for size) suggesting that
these markers predominantly inﬂuence bone size. Increments
in bone size occur through a combination of longitudinal
bone growth (involving endochondral bone formation) and
radial expansion (involving periosteal apposition), which are
closely matched to ensure that bone shape is maintained
throughout the growth. Since the SNPs were related to
height and the associations with BMC, BMD and bone area
were attenuated adjusting for height, associations between var-
iants in the region and measures of bone mass may reﬂect a
primary inﬂuence on longitudinal growth. Alternatively, due
Table 3. Meta-analysis of P-values from two previous genome-wide association studies
Reference Sample rs10876432 rs2016266
Increaser allele P-value Increaser allele P-value
Lumbar spine BMD
Styrkarsdottir et al. (10) Icelandic GWAS discovery G 1.0   10
26 G 1.04   10
26
Styrkarsdottir et al. (10) Icelandic replication G 4.0   10
27 G 2.6   10
25
Styrkarsdottir et al. (10) Australian and Danish replication G 0.19 G 0.069
Richards et al. (9) Twins UK G 0.22 G 0.029
Overall G 9.9   10
211 G 2.8   10
210
Femoral neck BMD
Styrkarsdottir et al. (10) Icelandic GWAS discovery G 0.0052 G 0.0033
Styrkarsdottir et al. (10) Icelandic replication G 0.0053 G 0.27
Styrkarsdottir et al. 2008 (10) Australian and Danish replication G 0.021 G 0.21
Richards et al. 2008 (9) Twins UK G 0.052 G 0.0085
Overall G 3.1   10
25 G 0.00079
P-values are listed for each study and these are combined by Fisher’s method to produce an overall level of signiﬁcance.
Table 4. Association results for four SNPs in the region of Osterix in the com-
bined analysis after adjusting for height (combined set)
Combined set
Phenotype SNP n BETA
a SE
a P-value
BMD (g/cm
2)
rs2016266 5226 0.033 0.017 0.045
rs4759021 5225 0.038 0.017 0.021
rs6580942 5223 0.044 0.017 0.009
rs10876432 5114 0.019 0.012 0.058
BMC (g)
rs2016266 5226 0.013 0.013 0.310
rs4759021 5225 0.018 0.013 0.160
rs6580942 5223 0.020 0.013 0.109
rs10876432 5114 0.022 0.013 0.092
Bone area (cm
2)
rs2016266 5226 0.008 0.011 0.486
rs4759021 5225 0.010 0.011 0.360
rs6580942 5223 0.010 0.011 0.372
rs10876432 5114 0.019 0.012 0.097
aStandardized beta coefﬁcients and standard errors. The sign of the beta
coefﬁcient indicates the direction of effect per addition of minor allele.
1514 Human Molecular Genetics, 2009, Vol. 18, No. 8to the close relationship between longitudinal and periosteal
bone growth, variants in the Osterix region might inﬂuence
bone development in a fundamental way that impacts
equally on longitudinal and periosteal bone growth.
Although an association between markers in the Osterix
region and BMD was observed in both child and adult popu-
lations, in a previous genome-wide analysis performed in
adults, no association was observed between these markers
and adult height (21). This contrasts with the case for
HMGA2 variants, for which equivalent associations were
reported in children (based on analyses in ALSPAC) and
adults (22). Any tendency for the variants to affect height in
childhood but not in adults might reﬂect a role in the rate of
skeletal maturation without inﬂuencing ﬁnal height achieved.
That delayed skeletal maturation adversely affects peak bone
mass achieved without affecting ﬁnal stature, as may be the
case for the variants identiﬁed in this study, is consistent
with previous reports that pubertal age is inversely related to
peak bone mass in boys and girls (23,24).
In summary, we identiﬁed associations between four poly-
morphisms in the region of the Osterix gene and total body
BMD as assessed in the ALSPAC cohort at age 9 and with
hip BMD in an adult population. Although this association
in children was explained at least in part by an effect on
bone size, these markers do not appear to be related to
height in adults, suggesting they may affect rate of growth
but not the ﬁnal height achieved. Based on our ﬁndings,
further studies are justiﬁed to examine the role of osteoblast
transcription factors such as Osterix in regulating the rate of
skeletal maturation and to what extent the latter impacts on
peak bone mass and bone size. In particular, we are keen to
extend our studies to examine associations with more accurate
measures of bone dimensions, for example using peripheral
quantitative computer tomography (pQCT), which is currently
being undertaken in the ALSPAC cohort.
MATERIALS AND METHODS
ALSPAC participants
The Avon Longitudinal Study of Parents and their Children
(ALSPAC) is a population-based birth cohort study consisting
initially of over 13 000 women and their children recruited in
the county of Avon, UK in the early 1990s (15). Both mothers
and children have been extensively followed from the 8th
gestational week onwards using a combination of self-reported
questionnaires, medical records and physical examinations.
Biological samples including DNA have been collected for
10121 of the children from this cohort. Ethical approval was
obtained from the ALSPAC Law and Ethics committee and
relevant local ethics committees, and written informed
consent provided by all parents.
Whole body BMD of 5333 children with DNA was
measured by Dual energy X-ray absorptiometry (DXA)
when they reached 9 years of age (Lunar Prodigy). Total
body less head values were expressed as BMD, BMC and
bone area. Conventional BMD measures, obtained by dividing
BMC by bone area, represent an ‘areal’ density that is only
partially corrected for skeletal size. To provide a more accu-
rate estimate of bone mass independent of size, we derived a
further parameter from BMC, termed aBMC, by linear
regression of BMC on bone area. Adjusting BMC for bone
area by linear regression analysis in this way generates a vari-
able which, unlike areal BMD, is fully independent of skeletal
size (25). Scans exhibiting evidence of artefacts were removed
from further analyses. All bone measures were approximately
normally distributed and therefore not transformed. Based
upon comparisons performed on 122 children who had two
BMD scans performed on a single day, the coefﬁcient of vari-
ation for total body BMD was 0.8. Children’s standing height,
sitting height and leg length was also measured using a Har-
penden Stadiometer. Weight was quantiﬁed using a Tanita
Body Fat Analyser. Body mass index (BMI) was calculated
as weight in kilograms divided by height in metres squared.
Both weight and BMI were log10 transformed prior to analysis
in order to improve the shape of the distributions. Children’s
pubertal development was assessed by Tanner score. Children
were deﬁned as pre-pubertal (i.e. Tanner Stage I) and pubertal
otherwise (i.e. Tanner Stage II and above).
Australian participants
One hundred and thirty-ﬁve unrelated subjects were recruited
from four Australian population studies, including the Dubbo
Osteoporosis Epidemiology Study (26), Geelong Osteoporosis
Study (27), Tasmanian Older Adult Cohort (28), and the
Calcium Intake Fracture Outcome Study (29), as well as
from the Oxford Family Osteoporosis Study (30), a study of
British families recruited via probands with low BMD
(z-score ,22). Subjects selected from these cohorts were
unrelated white Caucasian women .55 years of age but
.80 years of age, and ,5 years post-menopausal. Screening
had been performed for secondary causes of osteoporosis, and
subjects had not been taking osteoporosis agents prior to bone
Table 5. Association of SNPs in and around Osterix with growth-related phenotypes at age 9 (combined set)
rs2016266 rs4759021 rs6580942 rs10876432
n BETA
a SE
a P-value n BETA
a SE
a P-value n BETA
a SE
a P-value n BETA
a SE
a P-value
Height 5624 0.082 0.020 0.000037 5621 0.058 0.020 0.0035 5614 0.065 0.020 0.0011 5503 0.077 0.021 0.00022
Sitting height 5669 0.069 0.020 0.00046 5664 0.053 0.020 0.0072 5660 0.062 0.020 0.0018 5545 0.064 0.021 0.0018
Leg length 5669 0.077 0.020 0.00010 5664 0.051 0.020 0.010 5660 0.058 0.020 0.0036 5545 0.070 0.021 0.00067
Weight 5670 0.034 0.020 0.087 5665 0.016 0.020 0.408 5661 0.017 0.020 0.383 5546 0.041 0.020 0.043
BMI 5620 20.005 0.020 0.806 5617 20.013 0.020 0.525 5610 20.016 0.020 0.422 5499 0.0095 0.021 0.643
aStandardized beta coefﬁcients and standard errors. The sign of the beta coefﬁcient indicates the direction of effect per addition of minor allele.
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bone densitometry criteria (measured at the total hip), having
either low BMD (z-scores .24 but ,21.5, n= 69), or high
BMD (z-scores .+1.5 but ,+4, n =66). All subjects provided
written, informed consent, and each study was approved by its
Ethics review committee.
Genotyping
One thousand ﬁve hundred and forty-three ALSPAC individ-
uals and 135 Australian unrelated subjects were initially gen-
otyped using the Illumina HumanHap317K SNP chip. This
chip contains 317 504 SNPs and provides 75% genomic
coverage of the Utah CEPH (CEU) HapMap samples for
common SNPs at r
2 . 0.8 (31). Markers with minor allele fre-
quency ,1%, SNPs with .5% missing genotypes and, any
marker that failed an exact test of Hardy–Weinberg equili-
brium (P , 10
27) were excluded from further analyses.
After data cleaning, 315 807 SNPs were left in the ALSPAC
genome-wide association analysis, and 312 726 SNPs in the
Australian analysis. Follow-up genotyping of four SNPs
(rs2016266, rs4759021, rs6580942, rs10876432) that showed
the best evidence of association across both datasets was
carried out in the entire ALSPAC cohort for whom DNA
was available (i.e. 10 121 individuals) by K-Biosciences
(http://www.kbioscience.co.uk), who employ a novel form of
competitive allele speciﬁc PCR (KASPar) and TaqmanTM
system for genotyping.
Statistical analysis
Genome-wide identity by state sharing was calculated for each
pair of individuals in both cohorts to identify cryptic related-
ness. In order to identify individuals who might have ances-
tries other than Western European, we merged data from
both cohorts with the 60 western European (CEU) founder,
60 Nigerian (YRI) founder and 90 Japanese (JPT) and Han
Chinese (CHB) individuals from the International HapMap
Project (32). Genome-wide IBS distances for each pair of indi-
viduals were calculated on markers shared between the
HapMap and the Illumina 317K SNP chip, and then the multi-
dimensional scaling option in R was used to generate a two-
dimensional plot based upon individuals’ scores on the ﬁrst
two principal coordinates from this analysis. Samples that
did not cluster with the CEU individuals were excluded
from subsequent analyses. In addition, we plotted the pro-
portion of missing data for each individual against their
genome-wide heterozygosity. Any individual, who did not
cluster with others (i.e. with .5% missing data, a genome-
wide heterozygosity .36.4% or ,34.3%) was removed
from further analyses. Finally, we removed a single-male indi-
vidual in the ALSPAC cohort who scored heterozygous at
many loci on the X chromosome. After data cleaning, we
were left with 1518 individuals in the ALSPAC cohort
(1418 of whom had bone density measurements), and 66 indi-
viduals with high and 68 individuals with low bone density in
the Australian study.
Association analyses were performed in the ALSPAC
cohort for BMD, BMC, bone area and aBMC using least
squares linear regression assuming an additive model for gen-
otypes and including sex as a covariate. Tests for association
in the Australian cohort were performed using the Cochrane
Armitage trend test. Analyses were performed using STATA
and PLINK (33). QQ plots as well as small values of l
(from 1.005 to 1.02), the genomic-control inﬂation factor
(34), indicated only a small degree of population substructure
in both samples. We therefore report uncorrected results for all
our analyses.
Meta-analysis
We combined results from the previously published Richards
et al. (9) and Icelandic (10) genome-wide association studies
in the Osterix region using Fisher’s inverse chi-square test
(35) in order to estimate overall signiﬁcance:
S ¼  2
X n
i¼1
lnPi
where n is the number of independent studies being combined
and Pi is the P-value from the ith test. The statistic is distrib-
uted as a chi-square statistic with 2N degrees of freedom under
the null hypothesis.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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